Virtu Financial Portfolio holdings
Virtu Financial LLC is the operating company at the base of Virtu Financial, Inc., the electronic market maker, which controls it and runs all of its businesses. Virtu was co-founded in 2008 by Vincent Viola, who earlier chaired the New York Mercantile Exchange, along with Douglas Cifu, its chief executive until 2025, and Graham Free. It posts prices to buy and sell securities on markets around the world and sells execution services, data and analytics to clients. Virtu merged with the trading firm Madison Tyler in 2011, bought rival market maker KCG Holdings in 2017, and acquired the agency broker Investment Technology Group in 2019.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPDR Gold Trust
GLD
|
+$179M |
| 2 |
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
|
+$73.2M |
| 3 |
Strategy Inc
MSTR
|
+$47.8M |
| 4 |
Oracle
ORCL
|
+$45.6M |
| 5 |
Berkshire Hathaway Class A
BRK.A
|
+$41.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sandisk
SNDK
|
+$160M |
| 2 |
Micron Technology
MU
|
+$72.9M |
| 3 |
Goldman Sachs Physical Gold ETF Shares
AAAU
|
+$19.1M |
| 4 |
United States Brent Oil Fund
BNO
|
+$13.9M |
| 5 |
Microsoft
MSFT
|
+$13.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 35.6% |
| 2 | Miscellaneous | 19.47% |
| 3 | Technology | 15.78% |
| 4 | Financials | 11.49% |
| 5 | Industrials | 5.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1376
Milestone Pharmaceuticals
MIST
$95M
| $16K | ﹤0.01% |
+11,613
| New | +$18.6K |
2026 Q2
0 quarters
|
|
1377
MEDIROM Healthcare Technologies
MRM
$2.22M
| $16K | ﹤0.01% |
+15,785
| New | +$17.7K |
2026 Q2
0 quarters
|
|
1378
Tantech Holdings
TANH
$7.79M
| $16K | ﹤0.01% |
+840
| New | +$17.1K |
2026 Q2
0 quarters
|
|
1379
TruGolf
TRUG
$633K
| $16K | ﹤0.01% |
+1,235
| New | +$26.3K |
2026 Q2
0 quarters
|
|
1380
Blue Acquisition Corp Right
BACCR
| $16K | ﹤0.01% |
+20,176
| New | +$6.99K |
2026 Q2
0 quarters
|
|
|
MGN
1381
Megan Holdings Ltd
MGN
$61M
| $16K | ﹤0.01% |
+3,585
| New | +$18.6K |
2026 Q2
0 quarters
|
|
1382
Insight Digital Partners II Warrants
DYORW
| $16K | ﹤0.01% |
53,242
+11,154
| +27% | +$3.21K |
2025 Q4
2 quarters
|
|
1383
Paradium.AI, Inc.
PAAI
$42.5M
| $15K | ﹤0.01% |
+18,321
| New | +$31.8K |
2026 Q2
0 quarters
|
|
1384
CDT Equity Inc
CDT
$1.33M
| $15K | ﹤0.01% |
+5
| New | +$51.7K |
2026 Q2
0 quarters
|
|
1385
Enveric Biosciences
ENVB
$6.36M
| $15K | ﹤0.01% |
+10,690
| New | +$25.7K |
2026 Q2
0 quarters
|
|
1386
5E Advanced Materials
FEAM
$94.8M
| $15K | ﹤0.01% |
+10,788
| New | +$18K |
2026 Q2
0 quarters
|
|
1387
DELISTED
Visionary Holdings
GV
| $15K | ﹤0.01% |
74,776
+54,786
| +274% | +$13.5K |
2025 Q4
2 quarters
|
|
1388
EnerSyn Global Inc. Common Stock
ESYN
$12.6M
| $15K | ﹤0.01% |
+10,580
| New | +$12.4K |
2026 Q2
0 quarters
|
|
1389
Investcorp Credit Management BDC
ICMB
$8.81M
| $15K | ﹤0.01% |
+12,991
| New | +$19.3K |
2026 Q2
0 quarters
|
|
|
UZX
1390
Linkage Global
UZX
$3.57M
| $15K | ﹤0.01% |
+1,873
| New | +$30.1K |
2026 Q2
0 quarters
|
|
1391
Nerdy
NRDY
$53M
| $15K | ﹤0.01% |
+1,107
| New | +$14.5K |
2026 Q2
0 quarters
|
|
1392
Arcadia Biosciences
RKDA
$388K
| $15K | ﹤0.01% |
+21,786
| New | +$22.6K |
2026 Q2
0 quarters
|
|
1393
VistaGen Therapeutics
VTGN
$7.27M
| $15K | ﹤0.01% |
+66,021
| New | +$39.8K |
2026 Q2
0 quarters
|
|
1394
Health In Tech Inc
HIT
$36.4M
| $15K | ﹤0.01% |
+15,072
| New | +$18.7K |
2026 Q2
0 quarters
|
|
1395
Eastern International Ltd
ELOG
$7.94M
| $15K | ﹤0.01% |
+17,436
| New | +$16.2K |
2026 Q2
0 quarters
|
|
1396
Hennessy Capital Investment Corp VIII Share Rights
HCICR
| $15K | ﹤0.01% |
90,166
+166
| +0.2% | +$27 |
2026 Q1
1 quarter
|
|
1397
Accuray
ARAY
$13.2M
| $14K | ﹤0.01% |
+54,499
| New | +$20.3K |
2026 Q2
0 quarters
|
|
1398
Inuvo
INUV
$6.76M
| $14K | ﹤0.01% |
11,154
-5,945
| -35% | -$10K |
2026 Q1
1 quarter
|
|
1399
Lotus Technology
LOT
$210M
| $14K | ﹤0.01% |
12,121
-9,376
| -44% | -$11.9K |
2026 Q1
1 quarter
|
|
1400
Citius Oncology
CTOR
$53.9M
| $14K | ﹤0.01% |
+21,877
| New | +$17.4K |
2026 Q2
0 quarters
|
|
Similar funds
Virtu Financial's Q2 2026 Portfolio in Review
As of Q2 2026, Virtu Financial held 2,546 positions worth $3.18B, up 32% from $2.41B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Virtu Financial deployed $382M of net new capital in Q2 2026, opening 974 new positions and adding to 269 existing holdings. Its largest new stake was SPDR Gold Trust: 431,046 shares worth $159M.
By sector, the portfolio is most concentrated in Communication Services at 36% of assets, down from 36% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was Sandisk, an estimated $160M trimmed.
- Virtu Financial's largest Q2 2026 buy was SPDR Gold Trust: 431,046 shares worth $159M.
- Virtu Financial added most to State Street SPDR Dow Jones Industrial Average ETF Trust in Q2 2026, an estimated $73.2M increase.
- Virtu Financial's biggest Q2 2026 reduction was Sandisk, cutting an estimated $160M.
- Virtu Financial fully exited VanEck Merk Gold Trust in Q2 2026, selling an estimated $11.7M.
- Virtu Financial's ten largest holdings make up 54% of its $3.18B portfolio in Q2 2026.
- Virtu Financial opened 974 new positions and closed 998 in Q2 2026.
- Virtu Financial's portfolio value rose 32% quarter-over-quarter to $3.18B.
Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.